Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 293

The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.

Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities

Open access
Choudhury, Abrar, Magill, Stephen T., Eaton, Charlotte D., Prager, Briana C., Chen, William C., Cady, Martha A., Seo, Kyounghee, Lucas, Calixto-Hope G., Casey-Clyde, Tim J., Vasudevan, Harish N., Liu, S. John, Villanueva-Meyer, Javier E., Lam, Tai-Chung, Pu, Jenny Kan-Suen, Li, Lai-Fung, Leung, Gilberto Ka-Kit, Swaney, Danielle L., Zhang, Michael Y., Chan, Jason W., Qiu, Zhixin, Martin, Michael V., Susko, Matthew S., Braunstein, Steve E., Bush, Nancy Ann Oberheim, Schulte, Jessica D., Butowski, Nicholas, Sneed, Penny K., Berger, Mitchel S., Krogan, Nevan J., Perry, Arie, Phillips, Joanna J., Solomon, David A., Costello, Joseph F., McDermott, Michael W., Rich, Jeremy N., Raleigh, David R.·2022·Nature Genetics

Abstract

Meningiomas are the most common primary intracranial tumors. There are no effective medical therapies for meningioma patients, and new treatments have been encumbered by limited understanding of meningioma biology. Here, we use DNA methylation profiling on 565 meningiomas integrated with genetic, transcriptomic, biochemical, proteomic and single-cell approaches to show meningiomas are composed of three DNA methylation groups with distinct clinical outcomes, biological drivers and therapeutic vulnerabilities. Merlin-intact meningiomas (34%) have the best outcomes and are distinguished by NF2/Merlin regulation of susceptibility to cytotoxic therapy. Immune-enriched meningiomas (38%) have intermediate outcomes and are distinguished by immune infiltration, HLA expression and lymphatic vessels. Hypermitotic meningiomas (28%) have the worst outcomes and are distinguished by convergent genetic and epigenetic mechanisms driving the cell cycle and resistance to cytotoxic therapy. To translate these findings into clinical practice, we show cytostatic cell cycle inhibitors attenuate meningioma growth in cell culture, organoids, xenografts and patients. DNA methylation profiling of 565 meningiomas highlights three groups associated with distinct molecular, clinical and therapeutic features.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41588-022-01061-8

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 93 references

Cited by

See all 293

Metadata

Authors
Choudhury, A., Magill, S. T., Eaton, C. D., Prager, B. C., Chen, W. C., Cady, M. A., Seo, K., Lucas, C.-H. G., Casey-Clyde, T. J., Vasudevan, H. N., Liu, S. J., Villanueva-Meyer, J. E., Lam, T.-C., Pu, J. K.-S., Li, L.-F., Leung, G. K.-K., Swaney, D. L., Zhang, M. Y., Chan, J. W., Qiu, Z., Martin, M. V., Susko, M. S., Braunstein, S. E., Bush, N. A. O., Schulte, J. D., Butowski, N., Sneed, P. K., Berger, M. S., Krogan, N. J., Perry, A., Phillips, J. J., Solomon, D. A., Costello, J. F., McDermott, M. W., Rich, J. N., & Raleigh, D. R.
Venue
Nature Genetics
Published
2022-05
Volume
54
Issue
5
Pages
649-659
ISSN
  • 1061-4036 (ISSN-L)
  • 1546-1718
OpenAlex
W4229449309
Cited by
293
References
93
FWCI
36.74
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. https://app.cochat.ai/papers/10.1038/s41588-022-01061-8
The paper
Choudhury, A., Magill, S. T., Eaton, C. D., Prager, B. C., Chen, W. C., Cady, M. A., Seo, K., Lucas, C.-H. G., Casey-Clyde, T. J., Vasudevan, H. N., Liu, S. J., Villanueva-Meyer, J. E., Lam, T.-C., Pu, J. K.-S., Li, L.-F., Leung, G. K.-K., Swaney, D. L., Zhang, M. Y., Chan, J. W., . . . Raleigh, D. R. (2022). Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. Nature Genetics. https://doi.org/10.1038/s41588-022-01061-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.